Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist.
Laboratory research including animal models of human disease suggests that cannabinoids might have therapeutic potential in multiple sclerosis (MS). We have recently seen a 46-year-old woman who developed MS after starting treatment with a cannabinoid receptor antagonist for obesity. The occurrence of MS several months after starting a cannabinoid receptor antagonist suggests that the cannabinoid system might indeed be relevant to disease pathogenesis in MS.
van Oosten
B W
BW
Department of Neurology, VU University Medical Centre, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands. bw.vanoosten@vumc.nl
Killestein
J
J
Mathus-Vliegen
E M H
EM
Polman
C H
CH
D001067:Appetite Depressants / Q000009:adverse effects*; D063387:Cannabinoid Receptor Antagonists; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000139:chemically induced* / Q000473:pathology; D009765:Obesity / Q000188:drug therapy*; D010880:Piperidines / Q000009:adverse effects*; D011720:Pyrazoles / Q000009:adverse effects*; D043882:Receptors, Cannabinoid / Q000502:physiology; D000077285:Rimonabant
D001067:Appetite Depressants; D063387:Cannabinoid Receptor Antagonists; D010880:Piperidines; D011720:Pyrazoles; D043882:Receptors, Cannabinoid; D000077285:Rimonabant